DCM
ZNTL icon

Driehaus Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Driehaus Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-118,424
Closed -$6.15M – 529
2020
Q4 		$6.15M Buy
+118,424
New +$5.34M 0.1% 231

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Driehaus Capital Management's ZNTL Position: Q1 2021 in Review

Driehaus Capital Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2021, closing a stake of 118,424 shares — an estimated $6.15M sold.

Driehaus Capital Management first reported a position in ZNTL in Q4 2020 and held it in 1 quarter. The position peaked at $6.15M in Q4 2020. 95 funds tracked by Wall St. Rank hold ZNTL as of Q1 2021.

  • Driehaus Capital Management reported no remaining Zentalis Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Driehaus Capital Management sold 118,424 Zentalis Pharmaceuticals shares in Q1 2021, an estimated $6.15M.
  • Driehaus Capital Management first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Driehaus Capital Management's Zentalis Pharmaceuticals position peaked at $6.15M in Q4 2020.
  • 95 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2021.

Based on Driehaus Capital Management's 13F filing for Q1 2021, filed 17 May 2021.